Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835
Books209
All textbooksMedical textbooksHuman anatomyOrganisms & biodiversityOther sciences
Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›Antipsychotic discontinuation and reduction in people with schizophrenia and multiple-episode psychosis: the RADAR mixed-methods research programme including RCT›References

Continue where you left off ()

GO BEYOND THE PAGEReading is just the beginning.

Turn scientific reading into research. Compare studies, examine evidence, and organize your findings in EvidenceHelix Workspace.

Explore Research Workspace →

Antipsychotic discontinuation and reduction in people with schizophrenia and multiple-episode psychosis: the RADAR mixed-methods research programme including RCT · References

References

CC BY 4.0 · National Institute for Health and Care Research · approximately 8 min read

  1. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008;30:67–76. 10.1093/epirev/mxn00118480098
  2. McCrone P, Dhanasiri S, Patel A, Knapp M, Lawton-Smith S. Paying the Price: The Cost of Mental Health Care in England to 2026. London: King's Fund; 2008.
  3. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Focus (Am Psychiatr Publ) 2020;18:443–55. 10.1176/appi.focus.1830633343258
  4. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012;379:2063–71. 10.1016/S0140-6736(12)60239-622560607
  5. Baldessarini RJ, Tondo L. Effects of treatment discontinuation in clinical psychopharmacology. Psychother Psychosom 2019;88:65–70. 10.1159/00049733430923289
  6. Moncrieff J. Antipsychotic maintenance treatment: time to rethink? PLOS Med 2015;12:e1001861. 10.1371/journal.pmed.100186126241954
  7. Harrow M, Jobe TH, Faull RN. Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychol Med 2012;42:2145–55. 10.1017/S003329171200022022340278
  8. Wils RS, Gotfredsen DR, Hjorthoj C, Austin SF, Albert N, Secher RG, et al. Antipsychotic medication and remission of psychotic symptoms 10 years after a first-episode psychosis. Schizophr Res 2017;182:42–8. 10.1016/j.schres.2016.10.03028277310
  9. Moilanen JM, Haapea M, Jääskeläinen E, Veijola JM, Isohanni MK, Koponen HJ, Miettunen J. Long-term antipsychotic use and its association with outcomes in schizophrenia: the Northern Finland birth cohort 1966. Eur Psychiatry 2016;36:7–14. 10.1016/j.eurpsy.2016.03.00227311102
  10. Tiihonen J, Tanskanen A, Taipale H. 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry 2018;175:765–73. 10.1176/appi.ajp.2018.1709100129621900
  11. Ran MS, Weng X, Chan CL, Chen EY, Tang CP, Lin FR, et al. Different outcomes of never-treated and treated patients with schizophrenia: 14-year follow-up study in rural China. Br J Psychiatry 2015;207:495–500. 10.1192/bjp.bp.114.15768526382951
  12. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 2007;68:654–61. 10.4088/jcp.v68n050217503973
  13. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 2013;70:913–20. 10.1001/jamapsychiatry.2013.1923824214
  14. Hui CLM, Honer WG, Lee EHM, Chang WC, Chan SKW, Chen ESM, et al. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry 2018;5:432–42. 10.1016/S2215-0366(18)30090-729551618
  15. Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom’s General Practice Rsearch Database. Arch Gen Psychiatry 2007;64:242–9. 10.1001/archpsyc.64.2.24217283292
  16. Yood MU, DeLorenze G, Quesenberry CP Jr, Oliveria SA, Tsai AL, Willey VJ, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent: results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 2009;18:791–9. 10.1002/pds.178119526626
  17. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21:151–6. 10.1097/YCO.0b013e3282f53118332662
  18. Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev 2013;37:1680–91. 10.1016/j.neubiorev.2013.06.00123769814
  19. Hatano M, Kamei H, Kato A, Takeuchi I, Hanya M, Uno J, et al. Assessment of the latent adverse events of antipsychotic treatment using a subjective questionnaire in Japanese patients with schizophrenia. Clin Psychopharmacol Neurosci 2017;15:132–7. 10.9758/cpn.2017.15.2.13228449560
  20. Moncrieff J, Cohen D, Mason JP. The subjective experience of taking antipsychotic medication: a content analysis of Internet data. Acta Psychiatr Scand 2009;120:102–11. 10.1111/j.1600-0447.2009.01356.x19222405
  21. Murray RM, Quattrone D, Natesan S, van Os J, Nordentoft M, Howes O, et al. Should psychiatrists be more cautious about the long-term use of antipsychotics? Br J Psychiatry 2016;209:361–5. 10.1192/bjp.bp.116.18268327802977
  22. Begemann MJH, Thompson IA, Veling W, Gangadin SS, Geraets CNW, van 't Hag E, et al. To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial. Trials 2020;21:147. 10.1186/s13063-019-3822-532033579
  23. Crellin NE, Priebe S, Morant N, Lewis G, Freemantle N, Johnson S, et al. An analysis of views about supported reduction or discontinuation of antipsychotic treatment among people with schizophrenia and other psychotic disorders. BMC Psychiatry 2022;22:185. 10.1186/s12888-022-03822-535291964
  24. Birchwood M, Smith J, Cochrane R, Wetton S, Copestake S. The Social Functioning Scale: The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br J Psychiatr 1990;157:853–9. 10.1192/bjp.157.6.853
  25. Priebe S, Watzke S, Hansson L, Burns T. Objective social outcomes index (SIX): a method to summarise objective indicators of social outcomes in mental health care. Acta Psychiatr Scand 2008;118:57–63. 10.1111/j.1600-0447.2008.01217.x18582348
  26. Priebe S, Huxley P, Knight S, Evans S. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). Int J Soc Psychiatry 1999;45:7–12. 10.1177/00207640990450010210443245
  27. Ramsay G, Haime Z, Crellin NE, Stansfeld JL, Priebe S, Long M, Moncrieff J. Recruitment to a trial of antipsychotic reduction: impact of an acceptability study. BMC Med Res Methodol 2023;23:78. 10.1186/s12874-023-01881-036991350
  28. Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res 2005;15:1277–88. 10.1177/104973230527668716204405
  29. Cooper RE, Hanratty E, Morant N, Moncrieff J. Mental health professionals’ views and experiences of antipsychotic reduction and discontinuation. PLOS ONE 2019;14:e0218711. 10.1371/journal.pone.021871131220160
  30. Moncrieff J, Crellin NE, Long MA, Cooper RE, Stockmann T. Definitions of relapse in trials comparing antipsychotic maintenance with discontinuation or reduction for schizophrenia spectrum disorders: a systematic review. Schizophr Res 2020;225:47–54. 10.1016/j.schres.2019.08.03531604607
  31. Burns T, Fiander M, Audini B. A Delphi approach to characterising ‘relapse’ as used in UK clinical practice. Int J Soc Psychiatry 2000;46:220–30. 10.1177/00207640000460030811075634
  32. San L, Serrano M, Canas F, Romero SL, Sánchez-Cabezudo A, Villar M. Towards a pragmatic and operational definition of relapse in schizophrenia: a Delphi consensus approach. Int J Psychiatry Clin Pract 2015;19:90–8. 10.3109/13651501.2014.100250125547440
  33. Hall W. Harm Reduction Guide to Coming Off Psychiatric Drugs and Withdrawal. 2nd edn. New York: The Icarus Project and Freedom Centre; 2013.
  34. Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry 2005;18:249–55. 10.1097/01.yco.0000165594.60434.8416639148
  35. Cardno AG, Jones LA, Murphy KC, Asherson P, Scott LC, Williams J, et al. Factor analysis of schizophrenic symptoms using the OPCRIT checklist. Schizophr Res 1996;22:233–9. 10.1016/s0920-9964(96)00060-69000320
  36. Williams J, Farmer AE, Ackenheil M, Kaufmann CA, McGuffin P. A multicentre inter-rater reliability study using the OPCRIT computerized diagnostic system. Psychol Med 1996;26:775–83. 10.1017/s003329170003779x8817712
  37. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991;48:739–45. 10.1001/archpsyc.1991.018103200630091883257
  38. Oosthuizen P, Emsley RA, Turner J, Keyter N. Determining the optimal dose of haloperidol in first-episode psychosis. J Psychopharmacol 2001;15:251–5. 10.1177/02698811010150040311769818
  39. Horowitz MA, Jauhar S, Natesan S, Murray RM, Taylor D. A Method for tapering antipsychotic treatment that may minimize the risk of relapse. Schizophr Bull 2021;47:1116–29. 10.1093/schbul/sbab01733754644
  40. Bebbington PE, Craig T, Garety P, Fowler D, Dunn G, Colbert S, et al. Remission and relapse in psychosis: operational definitions based on case-note data. Psychol Med 2006;36:1551–62. 10.1017/S003329170600857916911809
  41. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, Manber R. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25–40. 10.1080/00926230027862310693114
  42. Neil ST, Kilbride M, Pitt L, Nothard S, Welford M, Sellwood W, Morrison AP. The questionnaire about the process of recovery (QPR): a measurement tool developed in collaboration with service users. Psychosis 2009;1:145–55. 10.1080/17522430902913450
  43. Waddell L, Taylor M. A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. J Psychopharmacol 2008;22:238–43. 10.1177/026988110708797618541624
  44. Moncrieff J, Lewis G, Freemantle N, Johnson S, Barnes TRE, Morant N, et al. Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction). BMJ Open 2019;9:e030912. 10.1136/bmjopen-2019-030912
  45. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–76. 10.1093/schbul/13.2.2613616518
  46. Atkisson CC, Zwick R. The Client Satisfaction Questionnaire: psychometric properties and correlations with service utilisation and psychotherapy outcome. Eval Program Plann 1982;5:233–37. 10.1016/0149-7189(82)90074-x10259963
  47. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727–36. 10.1007/s11136-011-9903-x21479777
  48. Al-Janabi H, Flynn TN, Coast J. Development of a self-report measure of capability wellbeing for adults: the ICECAP-A. Qual Life Res 2012;21:167–76. 10.1007/s11136-011-9927-221598064
  49. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 1993;4:353–65. 10.2165/00019053-199304050-0000610146874
  50. Slupczynska-Kossobudzka E, Boguszewska L. Effects of community mobile team intervention in the Drewnica Hospital catchment area: 1 – patient outcome. Int J Soc Psychiatry 1999;45:207–15. 10.1177/00207640990450030810576087
  51. Hernández-Alava M, Pudney S. EQ5Dmap: a command for mapping between EQ-5D-3L and EQ-5D-5L. Stata J 2018;18:395–415. 10.1177/1536867X1801800207
  52. National Institute for Health and Care Excellence. Economic Evaluation. NICE Health Technology Evaluations: The Manual. London: NICE; 2022.
  53. Flynn TN, Huynh E, Peters TJ, Al-Janabi H, Clemens S, Moody A, Coast J. Scoring the ICECAP-A capability instrument: estimation of a UK general population tariff. Health Econ 2015;24:258–69. 10.1002/hec.301424254584
  54. NHS Improvement. NHS Reference Costs. London: NHS England; 2023.
  55. Joint Formulary Committee. British National Formulary. London: BMJ Group and Pharmaceutical Press; 2023.
  56. Curtis L, Burns A. Unit Costs of Health and Social Care 2020. London: Personal Social Service Research Unit; 2020.
  57. Moncrieff J, Crellin N, Stansfeld J, Cooper R, Marston L, Freemantle N, et al. Randomised controlled trial of antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial). Lancet Psychiatry 2023;10:848–59. 10.1016/S2215-0366(23)00258-437778356
  58. Bray G, Moncrieff J, Priebe S, Marston L, Lewis G, Haynes N, et al. Cost-utility analysis of antipsychotic reduction and discontinuation in patients with long-term schizophrenia and psychosis in English mental health trusts: the RADAR study. Value Health 2025;28:358–67. 10.1016/j.jval.2024.07.01739127250
  59. Morant N, Long M, Jayacodi S, Cooper R, Akther-Robertson J, Stansfeld J, et al. Experiences of reduction and discontinuation of antipsychotics: a qualitative investigation within the ‘RADAR’ trial. eClinicalMedicine 2023;64:102135. 10.1016/j.eclinm.2023.10213537936655
  60. Braun V, Clark V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77–101. 10.1191/1478088706qp063oa
  61. Braun V, Clarke V. Thematic analysis: a practical guide. London: Sage; 2021.
  62. Freudenthal R, Marston L, Stansfeld JL, Priebe S, Moncrieff J. How do participants in clinical trials compare with other patients with schizophrenia? Contemp Clin Trials Commun 2021;22:100803. 10.1016/j.conctc.2021.10080334195470
  63. Stockmann T, Odegbaro D, Timimi S, Moncrieff J. SSRI and SNRI withdrawal symptoms reported on an internet forum. Int J Risk Saf Med 2018;29:175–80. 10.3233/JRS-18001829758951
← SynopsisAdditional information →

Attribution. Joanna Moncrieff; Maria Long; Stefan Priebe; Johura Akther-Robertson; Thomas Barnes; George Bray et al. (2026). Antipsychotic discontinuation and reduction in people with schizophrenia and multiple-episode psychosis: the RADAR mixed-methods research programme including RCT. National Institute for Health and Care Research. Copyright © 2026 Moncrieff et al. Licensed under CC BY 4.0. NCBI Bookshelf NBK621865. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support